论文部分内容阅读
目的分析可能影响干扰素治疗慢性丙型肝炎疗效的因素。方法将慢性丙型肝炎62例，随机分成两组，治疗组42例应用干扰素治疗，对照组20例用一般保肝药物治疗，疗程6个月。分别于治疗前、疗程中及疗程后每隔3个月定期检测抗－HCVIgG和IgM，血清及本稍血单个核细胞（PBMC）中HCVRNA，ALT水平。疗程结束后致少随访1年．结果治疗结束及随访一年时治疗组和对照组的ALT的复常率为66．7％对300％和52．4％对15．0％，血清HCVRNAM转率分别为59．5％对15．0％和47．6％对10．0％。分析持久应答的影响因素，年轻、病程短，治疗前抗-HCVIgM抗体滴度高、PBMC中无HCV感染、病理诊断末合并肝硬化的患者对干扰素反应性较好。结论检测抗HCV-IgM及PBMC中HCVRNA可作为干扰素疗效的预测因素。
Objective To analyze the factors that may affect the efficacy of interferon in the treatment of chronic hepatitis C Methods Sixty-two patients with chronic hepatitis C were randomly divided into two groups. In the treatment group, 42 patients were treated with interferon. In the control group, 20 patients were treated with general hepatoprotective drugs for 6 months. The levels of HCV RNA and ALT in anti-HCVVIg and IgM, serum and PBMC were detected regularly before treatment, during treatment and after treatment every 3 months. Follow-up after treatment for at least 1 year. Results At the end of treatment and one year follow-up, the normalization rates of ALT in the treatment group and the control group were 66.7% vs 300% and 52.4% vs 15.0%, respectively, and the serum HCV RNAM rates were 59.5% .0% and 47.6% vs. 10.0%. Analysis of long-term response factors, young, short duration, anti-HCV antibody before treatment, high titers, HCV infection in PBMC, pathological diagnosis of patients with cirrhosis at the end of the better response to interferon. Conclusion The detection of HCV RNA in anti-HCV-IgM and PBMC can be used as predictors of the efficacy of interferon.